Form 4: ANAB CMO Lizzul Reports RSU Vesting, Stock Option Grant

AnaptysBio's Chief Medical Officer, Paul F. Lizzul, reported the vesting and settlement of restricted stock units, a related tax-driven share sale, and new grants of restricted stock units and stock options.

Summary

• Paul F. Lizzul, Chief Medical Officer of AnaptysBio, Inc. (ANAB), reported transactions involving the company's common stock and derivative securities.
• On January 6, 2026, Lizzul acquired 6,145 shares of common stock through the settlement of previously granted restricted stock units (RSUs).
• Following this, on January 7, 2026, Lizzul sold 2,235 shares of common stock at $45.11 per share to cover tax withholding obligations related to the RSU vesting. This was a "sell to cover" transaction, not a discretionary sale.
• On January 6, 2026, Lizzul was granted 21,400 new restricted stock units, which will vest 25% annually starting January 6, 2027.
• Also on January 6, 2026, Lizzul received a grant of 29,000 stock options with an exercise price of $43.91. These options will vest 25% on January 6, 2027, and then 1/48th monthly until fully vested, expiring on January 5, 2036.
• After these transactions, Lizzul beneficially owns 37,213 shares of common stock directly.

Sentiment

Score: 7

Explanation: The filing reflects routine executive compensation activities, including RSU vesting, a tax-related share sale, and new equity grants. These actions are generally positive for executive retention and alignment with shareholder interests, indicating stability in compensation practices. The non-discretionary nature of the sale prevents it from being viewed negatively.

Positives

• Grant of 21,400 new Restricted Stock Units (RSUs) to the Chief Medical Officer, indicating continued long-term incentive and alignment with company performance.
• Grant of 29,000 new stock options with an exercise price of $43.91, providing further long-term incentive for the Chief Medical Officer.
• Vesting of 6,145 previously granted Restricted Stock Units, representing a realized compensation event for the executive.

Future Outlook

The filing indicates future vesting schedules for the Chief Medical Officer's equity compensation. The 21,400 Restricted Stock Units will vest 25% annually starting January 6, 2027, and the 29,000 stock options will vest 25% on January 6, 2027, followed by monthly vesting until fully vested, with an expiration date of January 5, 2036. This outlines a long-term incentive structure for the executive.

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and the grant of new equity awards. Such compensation structures, involving RSUs and stock options, are standard practice across the biotechnology and pharmaceutical industries to align executive incentives with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as a significant component of executive compensation is a common practice across the biotechnology sector, similar to companies like Amgen (AMGN) or Gilead Sciences (GILD), which frequently utilize such equity awards to attract and retain top talent and align management interests with shareholder returns.
• The "sell to cover" transaction for tax withholding is a standard mechanism for executives to manage tax liabilities upon the vesting of equity awards, widely observed in public companies across all industries.

Related Party Transactions

• The transactions involve an executive (Paul F. Lizzul) and the company (AnaptysBio, Inc.), which are considered related parties. These are standard compensation-related transactions.

Stakeholder Impact

• Shareholders: The grant of new equity awards to a key executive (CMO) can be seen as a positive for aligning management's long-term interests with shareholder value. The "sell to cover" transaction is a routine event and typically has minimal impact on share price or shareholder sentiment.
• Employees: The compensation structure for a senior executive may reflect broader compensation philosophies within the company, potentially influencing employee morale and retention.

Next Steps

• Continued vesting of 21,400 Restricted Stock Units annually commencing January 6, 2027.
• Continued vesting of 29,000 Stock Options, with 25% vesting on January 6, 2027, and monthly thereafter until fully vested.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, including RSU vesting, a tax-related share sale, and new equity grants. These are standard occurrences and do not typically provide new information that would significantly alter the investment thesis for AnaptysBio. The transactions reflect ongoing executive incentives rather than a change in company fundamentals or strategic direction, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

AnaptysBio, ANAB, Paul F. Lizzul, Chief Medical Officer, Form 4, SEC filing, Restricted Stock Units, RSU, Stock Options, Insider Transaction, Executive Compensation, Sell to Cover, Equity Grant